● TIER 3 — Information onlyGRADE A- (phase 3 RCTs)GLP-1 / incretins & amylin
Chinese GLP-1 agonists: beinaglutide, PEG-loxenatide [NEW split]
Origin: China. Citations verified: yes. 2 human study record(s) in the FitClinicMD studies database.
GOALS · Weight loss
FDA status
Not an FDA-approved product
Compounding (503A/503B)
Status varies — see notes
DEA
Not listed as controlled
WADA (sport)
Not specified
Human evidence · 2
Beinaglutide phase 3 RCT, Diabetes Obes Metab 2024.
PEG-loxenatide phase 3b add-on to metformin.
Reference only. This page summarizes publicly available regulatory and research information about Chinese GLP-1 agonists: beinaglutide, PEG-loxenatide [NEW split]. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.